Los Angeles Capital Management LLC Has $637,000 Stock Holdings in LifeMD, Inc. (NASDAQ:LFMD)

Los Angeles Capital Management LLC lifted its position in shares of LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 852.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 121,585 shares of the company's stock after acquiring an additional 108,822 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.28% of LifeMD worth $637,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quest Partners LLC bought a new stake in LifeMD in the second quarter valued at about $31,000. EntryPoint Capital LLC bought a new stake in LifeMD in the first quarter valued at about $89,000. nVerses Capital LLC bought a new stake in LifeMD in the third quarter valued at about $46,000. CWM LLC bought a new stake in LifeMD in the third quarter valued at about $59,000. Finally, SG Americas Securities LLC acquired a new position in LifeMD in the third quarter valued at about $70,000. Institutional investors own 35.52% of the company's stock.

LifeMD Price Performance

LFMD stock opened at $5.49 on Friday. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83. The business has a 50-day moving average of $4.99 and a 200-day moving average of $6.38. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $12.88.

Analysts Set New Price Targets

A number of research firms have issued reports on LFMD. Cantor Fitzgerald reissued an "overweight" rating and issued a $15.00 target price on shares of LifeMD in a research note on Friday, September 20th. B. Riley began coverage on LifeMD in a research note on Friday, August 23rd. They issued a "buy" rating and a $11.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of LifeMD in a research note on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.